Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using ...

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...

Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone HCl) Nasal Spray as the first FDA-approved ...

Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

Among pediatric patients with hereditary angioedema, on-demand sebetralstat was generally safe and used within a median time of 30 minutes after attack onset, according to interim phase 3 trial ...

Rise in high-acuity patients prompts hospitals like Mount Sinai and Novant Health to expand and renovate emergency departments.

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

In the phase 3 HER2CLIMB-02 trial, researchers evaluated the efficacy and safety of tucatinib plus T-DM1 compared to T-DM1 alone in HER2+ locally advanced or metastatic breast cancer.

Drugmaker Emergent BioSolutions is partnering with New York City-based Mount Sinai to test its experimental COVID-19 hyperimmune globulin treatment, COVID-HIG. Funded by $34.6 million from the ...